TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

HAE Treatment Guidelines

To help fill the gap in unmet needs for patients with hereditary angioedema (HAE), the International World Allergy Organization (WAO) and the European Academy of Allergy and Clinical Immunology (EAACI) have created consensus guidelines for the diagnosis and management of HAE.

When developing a treatment plan for your HAE patients, consider referring to the following evidence-based recommendations put forth by the WAO/EAACI.

Lexi, a real TAKHZYRO® (lanadelumab-flyo) patient, walking

Lexi

Real TAKHZYRO patient
Lexi, a real TAKHZYRO® (lanadelumab-flyo) patient, walking

Lexi

Real TAKHZYRO patient

WAO/EAACI Recommendations
for preventive treatment1

Preventive treatment, or long-term prophylaxis, refers to the use of regular medication to reduce the severity and frequency of HAE attacks. Preventive treatment should be individualized to meet the needs of each patient and take the following into consideration:

  • Severity and frequency of attacks
  • Past laryngeal attacks
  • Availability of healthcare resources
  • Patient’s personal preference

Since these factors can change over time, all patients with HAE should be evaluated for preventive treatment at every visit, at least once a year.

Clipboard icon

TAKHZYRO was assessed in one of the largest prevention studies in HAE with the longest treatment duration.2-4

See takhzyro efficacy

WAO/EAACI Recommendations for acute treatment1

Because HAE attacks can still occur despite the use of preventive treatment, all patients should have access to on-demand, or acute, treatment. Remind patients to always have acute treatment on hand.

Treatment icon

Encourage patients using TAKHZYRO to periodically check the date of acute treatment to make sure it hasn’t expired. Would you like to continue learning about acute treatment?

See one option

Partner with your patients

It’s important to create an individualized treatment plan in close partnership with your patients that includes an emergency plan.1 Working closely with patients will also help ensure that their treatment plan continues to evolve as needed.

Connect patients with support, including information on TAKHZYRO.

See patient resources

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-800-FDA-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

INDICATION

TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥12 years of age.

IMPORTANT SAFETY INFORMATION

Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, discontinue TAKHZYRO administration and institute appropriate treatment.

Adverse Reactions: The most commonly observed adverse reactions (≥10% and higher than placebo) associated with TAKHZYRO were injection site reactions consisting mainly of pain, erythema, and bruising at the injection site; upper respiratory infection; headache; rash; myalgia; dizziness; and diarrhea. Less common adverse reactions observed included elevated levels of transaminases; one patient discontinued the trial for elevated transaminases.

Use in Specific Populations: The safety and efficacy of TAKHZYRO in pediatric patients <12 years of age have not been established.

No data are available on TAKHZYRO in pregnant women. No data are available on the presence of lanadelumab in human milk or its effects on breastfed infants or milk production.

To report SUSPECTED ADVERSE REACTIONS, contact Dyax Corp., a Takeda company, at 1-800-FDA-2088, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information.

References: 1. Maurer M, Magerl M, Ansotegui I, et al. The international WAO/EAACI guideline for the management of hereditary angioedema – the 2017 revision and update. Allergy. doi:10.1111/all.13384. 2. TAKHZYRO (lanadelumab-flyo) [prescribing information]. Lexington, MA: Dyax Corp 2018. 3. HAEGARDA [prescribing information]. Kankakee, IL: CSL Behring LLC; 2017. 4. CINRYZE [prescribing information]. Lexington, MA: Shire ViroPharma Incorporated; 2018.